Across TCGA pan-cancer cohorts, CARNMT1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CARNMT1 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CARNMT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CARNMT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
KIRC, READ, and UCEC are the cancer types where CARNMT1 Mutation most reproducibly stratifies survival.